FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311756035> ?p ?o ?g. }

• W4311756035 abstract "Abstract Background The early evolution of extravalvular cardiac damage following transcatheter aortic valve replacement (TAVR) as assessed by a previous validated score system remains unstudied. We sought to assess the patterns of early cardiac damage change among patients with severe aortic stenosis (AS) undergoing TAVR and its prognostic implications. Methods The RECOVERY-TAVR is a multi-center, international retrospective registry including all consecutive patients undergoing TAVR in thirteen high-volume centers. All the enrolled patients with available paired echocardiography assessment pre- and post TAVR were included in this sub-analysis. Patients were categorized according to the extension of cardiac damage based on a previous published and validated classification (stage 0, no damage; stage 1, left ventricular damage; stage 2, left atrial or mitral valve damage; stage 3, pulmonary vasculature or tricuspid valve damage; and stage 4, right ventricular damage). The primary endpoint was a composite of all-cause mortality or first heart failure hospitalization at 1 year. The association of cardiac damage stage evaluated prior and following TAVR along with the staging evolution was assessed with multivariate Cox regression model (that include hemoglobin, NYHA class and max aortic valve gradient) for the primary outcome. Results Of 1331 Patients included in the RECOVERY-TAVR registry with a full echocardiographic pre-TAVR assessment, 892 patients with available paired echocardiography exams were finally included in this analysis (pre-TAVR assessment: median 8 days prior to TAVR; post-TAVR assessment: median 7 days post-TAVR). 63 (7.1%) had stage 0/1, 433 (48.2%) had stage 2, 235 (26.3%) had stage 3 and 161 (18%) had stage 4 myocardial damage. Pre-TAVR myocardial damage staging was associated with the primary outcome (Adj-HR for myocardial stage increase: HR 1.40, 95% CI 1.01–1.93). Following TAVR 274 (30.7%) patients experienced myocardial damage improvement and 161 (18.1%) myocardial damage worsening. Post-TAVR myocardial damage staging was more strongly associated with the primary outcome (HR 1.55, 95%CI 1.14–2.10) as compared to pre-TAVR assessment. Male Sex (p = 0.044) and post-procedural permanent pacemaker implantation (p = 0.044) was associated with myocardial damage worsening, while the use of a balloon-expandable valve (p = 0.011) was associated with myocardial damage improvement. Early myocardial damage worsening (HR 1.89, 95%CI 1.12–3.21), but not early myocardial damage improvement (HR 0.86, 95%CI 0.54–1.37) was associated with the primary outcome. Conclusion In patients undergoing TAVR, the extent of extravalvular cardiac damage prior to and early after TAVR has an independent prognostic value while early myocardial damage worsening following TAVR portends a poor prognosis. Whether strategies to improve procedural success and treatments addressing extravalvular myocardial damage early following TAVR may improve outcomes has to be prospectively assessed." @default.
• W4311756035 created "2022-12-28" @default.
• W4311756035 creator A5013597921 @default.
• W4311756035 creator A5015795674 @default.
• W4311756035 creator A5021276165 @default.
• W4311756035 creator A5024321268 @default.
• W4311756035 creator A5029557073 @default.
• W4311756035 creator A5030104535 @default.
• W4311756035 creator A5033373672 @default.
• W4311756035 creator A5034245665 @default.
• W4311756035 creator A5046197431 @default.
• W4311756035 creator A5053680565 @default.
• W4311756035 creator A5055478790 @default.
• W4311756035 creator A5057754911 @default.
• W4311756035 creator A5059801822 @default.
• W4311756035 creator A5059906206 @default.
• W4311756035 creator A5061235518 @default.
• W4311756035 creator A5073689871 @default.
• W4311756035 creator A5080362043 @default.
• W4311756035 creator A5081352924 @default.
• W4311756035 creator A5084414955 @default.
• W4311756035 creator A5087591276 @default.
• W4311756035 creator A5088557482 @default.
• W4311756035 creator A5088571005 @default.
• W4311756035 date "2022-12-14" @default.
• W4311756035 modified "2023-10-15" @default.
• W4311756035 title "891 EARLY EVOLUTION OF CARDIAC DAMAGE STAGING FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT: PREVALENCE, CLINICAL PATTERNS AND PROGNOSTIC SIGNIFICANCE" @default.
• W4311756035 doi "https://doi.org/10.1093/eurheartjsupp/suac121.749" @default.
• W4311756035 hasPublicationYear "2022" @default.
• W4311756035 type Work @default.
• W4311756035 citedByCount "0" @default.
• W4311756035 crossrefType "journal-article" @default.
• W4311756035 hasAuthorship W4311756035A5013597921 @default.
• W4311756035 hasAuthorship W4311756035A5015795674 @default.
• W4311756035 hasAuthorship W4311756035A5021276165 @default.
• W4311756035 hasAuthorship W4311756035A5024321268 @default.
• W4311756035 hasAuthorship W4311756035A5029557073 @default.
• W4311756035 hasAuthorship W4311756035A5030104535 @default.
• W4311756035 hasAuthorship W4311756035A5033373672 @default.
• W4311756035 hasAuthorship W4311756035A5034245665 @default.
• W4311756035 hasAuthorship W4311756035A5046197431 @default.
• W4311756035 hasAuthorship W4311756035A5053680565 @default.
• W4311756035 hasAuthorship W4311756035A5055478790 @default.
• W4311756035 hasAuthorship W4311756035A5057754911 @default.
• W4311756035 hasAuthorship W4311756035A5059801822 @default.
• W4311756035 hasAuthorship W4311756035A5059906206 @default.
• W4311756035 hasAuthorship W4311756035A5061235518 @default.
• W4311756035 hasAuthorship W4311756035A5073689871 @default.
• W4311756035 hasAuthorship W4311756035A5080362043 @default.
• W4311756035 hasAuthorship W4311756035A5081352924 @default.
• W4311756035 hasAuthorship W4311756035A5084414955 @default.
• W4311756035 hasAuthorship W4311756035A5087591276 @default.
• W4311756035 hasAuthorship W4311756035A5088557482 @default.
• W4311756035 hasAuthorship W4311756035A5088571005 @default.
• W4311756035 hasBestOaLocation W43117560351 @default.
• W4311756035 hasConcept C126322002 @default.
• W4311756035 hasConcept C141071460 @default.
• W4311756035 hasConcept C146357865 @default.
• W4311756035 hasConcept C151730666 @default.
• W4311756035 hasConcept C164705383 @default.
• W4311756035 hasConcept C203092338 @default.
• W4311756035 hasConcept C2780007028 @default.
• W4311756035 hasConcept C2780026749 @default.
• W4311756035 hasConcept C535046627 @default.
• W4311756035 hasConcept C71924100 @default.
• W4311756035 hasConcept C86803240 @default.
• W4311756035 hasConceptScore W4311756035C126322002 @default.
• W4311756035 hasConceptScore W4311756035C141071460 @default.
• W4311756035 hasConceptScore W4311756035C146357865 @default.
• W4311756035 hasConceptScore W4311756035C151730666 @default.
• W4311756035 hasConceptScore W4311756035C164705383 @default.
• W4311756035 hasConceptScore W4311756035C203092338 @default.
• W4311756035 hasConceptScore W4311756035C2780007028 @default.
• W4311756035 hasConceptScore W4311756035C2780026749 @default.
• W4311756035 hasConceptScore W4311756035C535046627 @default.
• W4311756035 hasConceptScore W4311756035C71924100 @default.
• W4311756035 hasConceptScore W4311756035C86803240 @default.
• W4311756035 hasIssue "Supplement_K" @default.
• W4311756035 hasLocation W43117560351 @default.
• W4311756035 hasOpenAccess W4311756035 @default.
• W4311756035 hasPrimaryLocation W43117560351 @default.
• W4311756035 hasRelatedWork W2037507673 @default.
• W4311756035 hasRelatedWork W2462155031 @default.
• W4311756035 hasRelatedWork W2888691009 @default.
• W4311756035 hasRelatedWork W2922536977 @default.
• W4311756035 hasRelatedWork W2948933257 @default.
• W4311756035 hasRelatedWork W2955528009 @default.
• W4311756035 hasRelatedWork W3105719192 @default.
• W4311756035 hasRelatedWork W3203530546 @default.
• W4311756035 hasRelatedWork W4306253774 @default.
• W4311756035 hasRelatedWork W4323268176 @default.
• W4311756035 hasVolume "24" @default.
• W4311756035 isParatext "false" @default.
• W4311756035 isRetracted "false" @default.
• W4311756035 workType "article" @default.